

IDEXX Cancer Dx™ Panel:

Interpreting mast cell tumor (MCT) results for dogs with suspicion of disease

The IDEXX Cancer Dx Panel is intended for use as a screening test in apparently healthy, at-risk dogs.*
The algorithm presented here applies to dogs in which MCT is already suspected, which is outside the panel's current recommended use.

MCT negative

Does not rule out MCT

A negative result does not rule out presence of one or more mast cell tumors

If suspicion persists, cytology or biopsy and histopathology of concerning masses or abnormal tissue should be considered

MCT positive

**Supports a clinical diagnosis
of MCT in patient**

Consider further diagnostics, such as cytology or biopsy of concerning masses or abnormal tissue, and staging (sampling of local lymph nodes, imaging such as abdominal ultrasound)

Consultation with a veterinary oncologist could be considered before referral to determine next steps

Detection rates of mast cell tumors vary by clinical aggressiveness. Positive results are more common in high-grade cutaneous, biologically aggressive subcutaneous, and visceral tumors. The IDEXX Cancer Dx Panel has limited detection of low-grade cutaneous and subcutaneous tumors with low-grade features.

*At-risk dogs include all dogs ≥ 7 years old and high-risk breeds ≥ 4 years old.